OraSure Technologies (OraSure Technologies) Risk Assessment

View and export this data going back to 1992. Start your Free Trial

What is OraSure Technologies Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of OraSure Technologies is: Low Risk: Strong fundamentals, worth long-term holding.

Competitive Comparison of OraSure Technologies's Risk Assessment

For the Medical Instruments & Supplies subindustry, OraSure Technologies's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OraSure Technologies's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, OraSure Technologies's Risk Assessment distribution charts can be found below:

* The bar in red indicates where OraSure Technologies's Risk Assessment falls into.

OraSure Technologies (NAS:OSUR) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

OraSure Technologies Risk Assessment Related Terms

Thank you for viewing the detailed overview of OraSure Technologies's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

OraSure Technologies (OraSure Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OraSure Technologies Inc (NAS:OSUR) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

EP3:Germany

Address

220 East First Street, Bethlehem, PA, USA, 18015

Website

https://www.orasure.com

OraSure Technologies is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets most of its sales from the molecular solutions business, derived mainly from customers in the United States.

Executives

Kathleen Gallagher Weber	officer: Chief Product Officer	220 EAST FIRST STREET, BETHLEHEM PA 18017
Michele Marie Miller	officer: VP, Finance and Controller	220 EAST FIRST STREET, BETHLEHEM PA 18017
Robert W. Mcmahon	director	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Kenneth J Mcgrath	officer: Chief Financial Officer	C/O ORASURE TECHNOLOGIES, INC., 220 E. FIRST STREET, BETHLEHEM PA 18015
Ronny B Lancaster	director	ORASURE TECHNOLOGIES INC, 220 EAST FIRST STREET, BETHLEHEM PA 18015
Mara G. Aspinall	director	7381 NORTH MOON SPIRIT LANE, TUCSON AZ 85718
Nancy J Gagliano	director	33 GRANITE WAY, GRANTHAM NH 03753
Michael Celano	director	220 EAST FIRST STREET, BETHLEHEM PA 18015
Manner Carrie Eglinton	director, officer: President & CEO	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Scott Gleason	officer: Interim CFO/SVP IR	1809 SOUTH 2500 EAST, SALT LAKE CITY UT 84108
Eamonn P Hobbs	director	C/O DELCATH SYSTEMS, INC., 600 FIFTH AVENUE, NEW YORK NY 10020
Anne Clem Whitaker	director	109 BRIERY BRANCH COURT, MORRISVILLE NC 27560
James A Datin	director	21 ESTATES DRIVE, DOYLESTOWN PA 18901
Lelio Marmora	director	64 RUE DE VESENEX, DIVONNE LES BAINS I0 01220
Lisa Nibauer	officer: President of Diagnostics	1 CRESENT PLACE, SHORT HILLS NJ 07078